TRVI Trevi Therapeutics, Inc.
Healthcare$14.38+1.77%ClosedMarket Cap: $2.04B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
12.16
P/S
0.00
EV/EBITDA
-42.79
DCF Value
$0.11
FCF Yield
-1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-24.5%
ROA
-25.4%
ROIC
-30.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-14.9M | $-13.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-10.2M | $-8.3M | $— | — |
| FY null | $0.00 | NaN% | $-49.3M | $-42.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-13.9M | $-11.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-13.7M | $-12.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-11.5M | $-10.3M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-12.2M | $-11.4M | $— | — |
| FY null | $0.00 | NaN% | $-51.5M | $-47.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-14.1M | $-13.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-13.3M | $-12.4M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-11.9M | $-10.9M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-8.9M | $-7.8M | $-0.08 | — |